Emergent Biosolutions Faces Investor Revolt Over Botched Vaccines - The New York Times

by nytimes.com posted 3weeks ago 5 views
In the latest shareholder lawsuit, a pension fund accused executives at Emergent BioSolutions of insider trading. The company, under investigation by Congress, has halted manufacturing of Covid-19 vaccines at its Baltimore factory at regulators’ request.

In this article

No tags related to this article.